Skip to main content

Investor Relations

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies.

Ideaya Highlights

 
Investor Presentation
Recent News
Oct 4, 2024

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a late-breaking oral presentation of...

Sep 27, 2024

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 26, 2024, the...

Sep 23, 2024

Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with >30% tumor shrinkage by product of diameters,...

All Releases

Events
Monday, September 23, 2024
8:00am EDT

Pre-registration is available through the following link:
https://lifescievents.com/event/ideaya-3/

Wednesday, September 4, 2024
5:45pm EDT

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Judah Frommer, Executive Director, Senior Equity Research Analyst

All Events

Stock Info
NASDAQIDYA

Stock Information

Investor Contact

Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
650-443-6214
investor@ideayabio.com

Subscribe to email alerts
* Required Fields
WE ARE DEDICATED TO

Improving Lives Through Transformative Precision Medicines

Close Menu